Molecular Weight(MW): 236.23
Didanosine is a reverse transcriptase inhibitor with an IC50 of 0.49 μM.
Purity & Quality Control
Choose Selective Reverse Transcriptase Inhibitors
|Description||Didanosine is a reverse transcriptase inhibitor with an IC50 of 0.49 μM.|
Didanosine induces cytoplasmic lipid droplet accumulations, increases lactate production and decreases activities of COX (complex IV) and SDH (part of complex II) in cultured human muscle cells.  Didanosine is converted to its active moiety, dideoxyadenosine-5'-triphosphate (ddATP), which inhibits HIV reverse transcriptase and terminates viral DNA growth in the target cell for HIV.  Didanosine induces dose-dependent decreases in neurite number, length of the longest neurite in each neuron, and total neurite length per neuron in dissociated DRG cell cultures with 3 days treatment. Didanosine induces a neurite retraction or neurite loss in a dose-dependent manner in dissociated DRG neurons, suggesting that Didanosine may partially contribute to developing peripheral neuropathy.  Didanosine potentiates the mutagenicity of Zidovudine in the thymidine kinase (TK) gene of cultured human TK6 lymphoblastoid cells. Didanosine combined with Zidovudine causes a significant increase in micronucleated PCEs and induces a significant increase in Tk mutants, which is associated with loss of the wild-type Tk+ allele.  Didanosine depletes mitochondrial DNA (mtDNA) in cultured hepatocytes, this mtDNA depletion is associated with an increased in vitro production of lactate. 
|In vitro||DMSO||47 mg/mL (198.95 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT00928187||Completed||HIV|HIV Infections||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Gilead Sciences|Janssen Pharmaceutica||November 2009||Phase 3|
|NCT00668356||Suspended||HIV Infections||Assistance Publique - Hôpitaux de Paris||September 2009||Phase 2|
|NCT00091936||Completed||HIV Infections|Tuberculosis||National Institute of Allergy and Infectious Diseases (NIAID)||August 2009||--|
|NCT00427297||Terminated||HIV Infections||University of Washington|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||September 2007||Phase 3|
|NCT00364793||Completed||HIV Infections||Bristol-Myers Squibb||February 2007||Phase 1|Phase 2|
|NCT00332306||Unknown status||Tuberculosis|Human Immunodeficiency Virus Infections||Tuberculosis Research Centre, India|National AIDS Control Organisation|Indian Council of Medical Research||June 2006||Phase 3|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.